Cornerstone Therapeutics Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Chiesi Farmaceutici SpA’s Going Private Offer
February 21, 2013
Bernstein Liebhard LLP is investigating whether the Board of Directors of Cornerstone Therapeutics Inc. (“Cornerstone Therapeutics” or the “Company”) (NASDAQ: CRTX) and Chiesi Farmaceutici SpA (“Chiesi”), the majority shareholder of Cornerstone Therapeutics, are breaching their fiduciary duties to the Company’s shareholders in connection with an offer by Chiesi, to take the Company private.
Under the terms of the offer, Cornerstone Therapeutics shareholders will receive between $6.40 and $6.70 in cash for each share of common stock they own. The investigation is focused on whether Chiesi Farmaceutici SpA’s offer undervalues the Company’s shares.
If you are interested in discussing your rights as a Cornerstone Therapeutics shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last ten years.